Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Glecirasib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Glecirasib is a once-a-day targeted tablet for advanced non-small cell lung cancer (NSCLC) that carries the KRAS G12C mutation. It was developed by Jacobio Pharmaceuticals in Beijing (research code JAB-21822) and is sold in China by Shanghai Allist Pharmaceuticals as 艾瑞凯® (Airuikai).
China's National Medical Products Administration (NMPA) granted it conditional approval in May 2025 for adults with:
A validated test must confirm the mutation before use. It is a prescription lung cancer medicine and should only be used under an oncologist.
The KRAS protein normally flips between "on" and "off" to control cell growth. With the G12C mutation it stays switched on, so the tumour keeps growing. Glecirasib forms a permanent bond with the faulty protein while it is in its resting, GDP-bound state and keeps it locked there. This blocks the signals (such as ERK) that drive the cancer cells to multiply and can lead them to die.
According to Allist, it is the only KRAS G12C medicine approved in China that is taken just once a day.
The approval was based on the pivotal phase 2b part of the JAB-21822-1002 study in China, published in Nature Medicine in 2025. It enrolled 119 adults whose KRAS G12C lung cancer had grown after earlier treatment; 94.1% had already had both platinum chemotherapy and immunotherapy. In the updated results in the Chinese label:
This is a conditional approval based on a single-arm study. Full approval depends on a confirmatory trial.
If you miss a dose, take it as soon as you remember, as long as the next dose is at least 12 hours away; otherwise skip it. If you vomit, do not take another dose that day. For side effects, the dose can be lowered to 400 mg and then 200 mg once a day. It is stopped for good if a patient cannot tolerate 200 mg a day.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Liver effects: liver problems were seen in clinical trials. In 314 patients on the recommended dose, AST rose in 31.5% and ALT in 29.6%, and bilirubin rose in 58.6%, often on its own without enzyme changes. Liver injury occurred in 1.3% of patients; there were no liver-related deaths. Liver tests (ALT, AST and bilirubin) are checked every 3 weeks for the first 3 months, then monthly, and the dose is adjusted if needed.
Overall: serious side effects occurred in 12.4% of patients and severe (grade 3 or more) side effects in 39.5%. 34.4% needed a pause and 16.2% a lower dose, while 3.5% stopped because of side effects. Safety in children under 18 has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. If your tumour test shows a different change, our pages on Hernexeos (HER2-mutant) and Ibtrozi (ROS1-positive) cover other targeted lung cancer imports.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The 200 mg tablets come in blister strips of 10, in boxes of 10 or 40 tablets; a 40-tablet box lasts 10 days at the full dose of four tablets a day, so a month needs three boxes. The label says to store them below 30°C, sealed, away from light and in the original pack to protect them from moisture, and they travel that way under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.
Cancer hospitals in Delhi manage many lung cancer patients from North India, and our New Delhi dispatch point keeps delivery times short.
Oncologists in Mumbai can request the tablets for a named patient after sharing the prescription and KRAS G12C report.
Patients in Bangalore can receive their monthly supply at home or at the treating hospital.
A major South Indian centre for lung cancer treatment, with molecular testing readily available.
We plan supply so patients in Hyderabad have tablets ready before each review visit.
Patients in Kolkata and the north-east can use the same documented import route, with a clear quote first.
Oncologists in Pune can start the import by sending us the prescription and test results.
Patients across Gujarat can receive the tablets through their cancer hospital in Ahmedabad.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating oncologist.
The once-daily tablets can be taken at home, with refills delivered across Rajasthan.
We coordinate delivery to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can have the tablets delivered in Kochi and nearby cities, with updates at every step.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
